- Home
- GILD vs UBS Comparison
GILD vs UBS Comparison
Compare GILD & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | UBS |
|---|---|---|
| Founded | 1987 | 1862 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 135.5B |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GILD | UBS |
|---|---|---|
| Price | $128.48 | $42.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 2 |
| Target Price | ★ $148.39 | $60.30 |
| AVG Volume (30 Days) | ★ 4.4M | 2.4M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.52% | 1.33% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.68 | $7.40 |
| Revenue Next Year | $6.04 | $2.83 |
| P/E Ratio | $19.22 | ★ $17.22 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $95.30 | $29.73 |
| 52 Week High | $157.29 | $49.36 |
Technical Indicators
Market Signals| Indicator | GILD | UBS |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 55.68 |
| Support Level | $116.55 | $41.24 |
| Resistance Level | $142.33 | $42.57 |
| Average True Range (ATR) | 2.99 | 0.73 |
| MACD | -0.89 | -0.02 |
| Stochastic Oscillator | 1.09 | 40.37 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.